Research programme: neurodegenerative disease therapies - Eisai
Latest Information Update: 25 May 2010
At a glance
- Originator Eisai Co Ltd
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders